Benzinga | Nov 10, 2020 04:54PM EST

Curis: Q3 Earnings Insights

Shares of Curis (NASDAQ:CRIS) fell 0.88% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 42.11% year over year to ($0.11), which beat the estimate of ($0.13).

Revenue of $2,742,000 decreased by 3.99% from the same period last year, which beat the estimate of $2,570,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Curis hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 10, 2020

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1827/38600

Recent Stock Performance

52-week high: $3.59

Company's 52-week low was at $0.62

Price action over last quarter: down 15.11%

Company Profile

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.